Apr 4, 2025 · Our Therapies. NGENLA™ is an FDA-approved next-generation human growth hormone therapy for patients with pediatric growth hormone deficiency. Now approved in over …

Stable Innovation. Our company philosophy is to always be thinking one-step ahead by developing and delivering next-generation solutions that patients need to maintain leading …

RAYALDEE® is an extended-release (ER) oral formulation of calcifediol, a prohormone of calcitriol, the active form of vitamin D 3.The product is the first and only medicine approved by …

Dec 31, 2024 · On March 27, 2007, we were part of a merger with Froptix Corporation and Acuity Pharmaceuticals, Inc., both research and development companies. On June 8, 2007, we …

MIAMI, Feb. 13, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2024 …

MIAMI, Jan. 09, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 43 r d Annual J.P. Morgan Healthcare …

Sep 30, 2024 · opk NASDAQ Global Select Market Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange …

WESTON, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), announces dosing of the first participant in the Phase I …

Sep 16, 2024 · OPKO Health, Inc. (Nasdaq: OPK) is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly …

Apr 4, 2025 · OPKO Health, Inc. 4400 Biscayne Boulevard Miami, FL 33137 . T: 305-575-4100